Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
The objective of this report was to perform a systematic review of the beneficial and harmful effects of rotigotine for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD).
Contents
- Clinical Review Report
- ABBREVIATIONS
- EXECUTIVE SUMMARY
- 1. INTRODUCTION
- 2. OBJECTIVES AND METHODS
- 3. RESULTS
- 4. DISCUSSION
- 5. CONCLUSIONS
- APPENDIX 1. PATIENT INPUT SUMMARY
- APPENDIX 2. LITERATURE SEARCH STRATEGY
- APPENDIX 3. EXCLUDED STUDIES
- APPENDIX 4. DETAILED OUTCOME DATA
- APPENDIX 5. VALIDITY OF OUTCOME MEASURES
- APPENDIX 6. SUMMARY OF SUPPORTIVE STUDIES
- APPENDIX 7. SUMMARY OF COMPARATORS
- APPENDIX 8. CRITICAL APPRAISAL AND SUMMARY OF RESULTS OF THE MULTIPLE TREATMENT COMPARISON META-ANALYSIS
- REFERENCES
- Pharmacoeconomic Review Report
- CDEC FINAL RECOMMENDATION
This review report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). In addition to CADTH staff, the review team included a clinical expert in neurology who provided input on the conduct of the review and the interpretation of findings.
Through the Common Drug Review (CDR) process, CADTH undertakes reviews of drug submissions, resubmissions, and requests for advice, and provides formulary reimbursement recommendations to all Canadian publicly funded federal, provincial, and territorial drug plans, with the exception of Quebec.
The report contains an evidence-based clinical and/or pharmacoeconomic drug review, based on published and unpublished material, including manufacturer submissions; studies identified through independent, systematic literature searches; and patient-group submissions. In accordance with CDR Update — Issue 87, manufacturers may request that confidential information be redacted from the CDR Clinical and Pharmacoeconomic Review Reports.
The information in this report is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment with respect to the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this document to ensure that its contents are accurate, complete, and up-to-date as of the date of publication, CADTH does not make any guarantee to that effect. CADTH is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in the source documentation. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the information in this document or in any of the source documentation.
This document is intended for use in the context of the Canadian health care system. Other health care systems are different; the issues and information related to the subject matter of this document may be different in other jurisdictions and, if used outside of Canada, it is at the user’s risk. This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.
CADTH takes sole responsibility for the final form and content of this document, subject to the limitations noted above. The statements and conclusions in this document are those of CADTH and not of its advisory committees and reviewers. The statements, conclusions, and views expressed herein do not necessarily represent the views of Health Canada or any Canadian provincial or territorial government. Production of this document is made possible by financial contributions from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Ontario, Prince Edward Island, Saskatchewan, and Yukon.
- NLM CatalogRelated NLM Catalog Entries
- Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.[Clin Neuropharmacol. 2007]Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):256-65.
- Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.[Clin Neuropharmacol. 2015]Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.Ohta K, Osada T. Clin Neuropharmacol. 2015 Nov-Dec; 38(6):231-5.
- Review Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.[Neurol Clin. 2013]Review Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.Lyons KE, Pahwa R. Neurol Clin. 2013 Aug; 31(3 Suppl):S51-9. Epub 2013 Jun 14.
- Review Clinical Review Report: Safinamide (Onstryv): (Valeo Pharma Inc.): Indication: For add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing “off” episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD[ 2020]Review Clinical Review Report: Safinamide (Onstryv): (Valeo Pharma Inc.): Indication: For add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing “off” episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD. 2020 May
- Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.[Curr Med Res Opin. 2011]Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.Ceballos-Baumann A, Häck HJ. Curr Med Res Opin. 2011 Oct; 27(10):1899-905. Epub 2011 Aug 25.
- Rotigotine (Neupro) (Transdermal Patch)Rotigotine (Neupro) (Transdermal Patch)
- Concise Conserved Domain Links for Protein (Select 931484038) (1)Conserved Domains
Your browsing activity is empty.
Activity recording is turned off.
See more...